AB
BCRX icon

Amalgamated Bank’s BioCryst Pharmaceuticals BCRX Stock Holding History

Amalgamated Bank’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,581
Closed -$51K – 1752
2025
Q4 		$51K Sell
6,581
-574
-8% -$4.15K ﹤0.01% 1832
2025
Q3 		$54K Hold
7,155
– – ﹤0.01% 1819
2025
Q2 		$64K Hold
7,155
– – ﹤0.01% 1776
2025
Q1 		$54K Buy
7,155
+442
+7% +$3.56K ﹤0.01% 1788
2024
Q4 		$50K Hold
6,713
– – ﹤0.01% 1837
2024
Q3 		$51K Hold
6,713
– – ﹤0.01% 1840
2024
Q2 		$41K Buy
6,713
+366
+6% +$2.02K ﹤0.01% 1898
2024
Q1 		$32K Sell
6,347
-17,910
-74% -$101K ﹤0.01% 1982
2023
Q4 		$145K Sell
24,257
-1,889
-7% -$10.9K ﹤0.01% 1890
2023
Q3 		$185K Hold
26,146
– – ﹤0.01% 1815
2023
Q2 		$184K Buy
26,146
+1,926
+8% +$15.5K ﹤0.01% 1851
2023
Q1 		$202K Sell
24,220
-3,681
-13% -$35.4K ﹤0.01% 1799
2022
Q4 		$320K Hold
27,901
– – ﹤0.01% 1668
2022
Q3 		$352K Buy
27,901
+328
+1% +$4.22K ﹤0.01% 1594
2022
Q2 		$292K Buy
27,573
+4,481
+19% +$46.2K ﹤0.01% 1706
2022
Q1 		$375K Sell
23,092
-977
-4% -$15.7K ﹤0.01% 1674
2021
Q4 		$333K Sell
24,069
-93
-0.4% -$1.23K ﹤0.01% 1765
2021
Q3 		$347K Sell
24,162
-1,687
-7% -$26.6K ﹤0.01% 1776
2021
Q2 		$409K Buy
25,849
+2,809
+12% +$38.2K ﹤0.01% 1740
2021
Q1 		$234K Sell
23,040
-1,374
-6% -$14.2K 0.01% 1402
2020
Q4 		$182K Buy
24,414
+138
+0.6% +$711 0.01% 1463
2020
Q3 		$83K Buy
24,276
+2,228
+10% +$9.55K ﹤0.01% 1427
2020
Q2 		$105K Sell
22,048
-1,490
-6% -$5.95K ﹤0.01% 1392
2020
Q1 		$47K Buy
23,538
+3,497
+17% +$9.63K ﹤0.01% 1575
2019
Q4 		$69K Buy
20,041
+664
+3% +$1.67K ﹤0.01% 1770
2019
Q3 		$56K Sell
19,377
-140
-0.7% -$435 ﹤0.01% 1701
2019
Q2 		$74K Buy
19,517
+3,749
+24% +$22.6K ﹤0.01% 1718
2019
Q1 		$128K Buy
15,768
+596
+4% +$5.1K ﹤0.01% 1581
2018
Q4 		$122K Buy
+15,172
New +$118K ﹤0.01% 1502
2018
Q3 		– Sell
-14,835
Closed -$85K – 1464
2018
Q2 		$85K Buy
14,835
+1,646
+12% +$9.06K ﹤0.01% 1668
2018
Q1 		$63K Sell
13,189
-171
-1% -$879 ﹤0.01% 1554
2017
Q4 		$66K Buy
13,360
+3,171
+31% +$15.4K ﹤0.01% 1595
2017
Q3 		$53K Buy
+10,189
New +$52.2K ﹤0.01% 1541

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Amalgamated Bank's BCRX Position: Q1 2026 in Review

Amalgamated Bank sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 6,581 shares — an estimated $51K sold.

Amalgamated Bank first reported a position in BCRX in Q3 2017 and held it in 33 quarters. The position peaked at $409K in Q2 2021. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Amalgamated Bank reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 6,581 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $51K.
  • Amalgamated Bank first reported a position in BioCryst Pharmaceuticals in Q3 2017 and held it in 33 quarters.
  • Amalgamated Bank's BioCryst Pharmaceuticals position peaked at $409K in Q2 2021.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.